120results about How to "Expand clinical application" patented technology

The invention provides a full-automatic nucleic acid extraction and PCR amplification micro-fluidic chip which comprises at least one main body, wherein the main body is distributed in equal distance around the chip; the main body comprises a nucleic acid extraction unit, a PCR amplification unit, a waste liquid unit and an exhaust unit, wherein the nucleic acid extraction unit is positioned on the main body and is used for extracting, washing and eluting nucleic acid in sequence under the driving of centrifugal force and capillary force; the PCR amplification unit is adopted for PCR reaction amplification; the waste liquid unit comprises a waste liquid cavity which is used for storing a waste liquid; the exhaust unit comprises exhaust holes and a plurality of exhaust channels; and the plurality of exhaust channels are communicated with the nucleic acid extraction unit, the PCR amplification unit and the waste liquid unit and are used for exhausting air. The invention discloses a micro-fluidic chip for achieving full-automatic nucleic acid extraction and PCR reaction through centrifugal force, capillary force and siphon phenomenon, the micro-fluidic chip has no integrated equipment such as pumps or valves, so that the manufacturing difficulty and cost of the chip are greatly reduced, and moreover the reliability of the chip is improved.

A computed tomography system with an adjustable focal spot-to-detector distance has a gantry provided with a patient opening, an x-ray tube and a detector, respectively mounted at opposite sides of the gantry. The x-ray tube has a focal spot and the x-ray fan beam radiated from the focal spot exhibits a fixed aperture angle. The x-ray tube is installed on a linear track and can be moved along the rail of the linear track.

The invention provides a mussel mucoprotein gel for wound repair, and a preparation method and an application thereof. The mussel mucoprotein gel for wound repair comprises the following raw materials in percentage by weight: 0.15-0.2% of mussel mucoprotein, 0.1-5% of protein protector, 0.1-5% of tackifier, 0.1-5% of stabilizer, 0.1-5% of preservative, 1-10% of wetting agent, 0.1-5% of pH (potential of hydrogen), and 64.8-98.35% of medical dissolving water. With Carbomer as a substrate, the mussel mucoprotein gel has good extending property, is easy to coat and adhere on a skin, has no irritation to skin and mucosa and can absorb tissue penetrating fluid, so secretions can be exhausted conveniently; the gel is not greasy, the medicines are released fast, and the coupling effect with skin tissues is excellent.

The invention discloses a metabonomics-based diagnosis marker for chronic obstructive pulmonary disease and application thereof. The diagnosis marker comprises the following 28 blood plasma metabolismmarkers: phosphatidylcholine PC 16:1-36:3, phosphatidylcholine PC 26:0-22:4, phosphatidylcholine PC 26:0-22:3, phosphatidylcholine PC 47:5e, phosphatidylcholine PC 44:11e, phosphatidylcholine PC 16:0-24:5, phosphatidylcholine PC 20:2-20:3, phosphatidylcholine PC 40:10, phosphatidylcholine PC 38:9e, phosphatidylcholine PC 18:1-20:4, phosphatidylcholine PC 16:0-20:3, phenylacetaldehyde, dihydrouracil, nicotinamide, 4-methoxycinnamic acid, ketovaline, threonine, DL-3-aminoisobutyric acid, pyruvic acid, stachyose, caffeic acid, N, N-dimethylaniline, maltotriose, D(-)-gulonate-gamma-lactone, and L-asparaginase. The marker provided by the invention has good classification on metabolome data of patients suffering chronic obstructive pulmonary disease and healthy people, and can accurately distinguish the patients suffering chronic obstructive pulmonary disease from the healthy people.

The invention discloses an atractylone lipidosome containing atractylone and a lipidosome membrane material, wherein the atractylone is an Atractylis ovata extract, and the lipidosome membrane material is phosphatidylcholine or cholesterol. A method for preparing the atractylone lipidosome by adopting a supercritical fluid dispersing precipitation technology comprises the following steps of: (1) dissolving the atractylone and the lipidosome membrane material in a supercritical CO2/alcohol mixed solvent, then obtaining a supercritical solution; (2) dissolving a surface active agent as a stabilizer in an aqueous medium, then obtaining a stabilizer solution; (3) and rapidly jetting the supercritical solution to the stabilizer solution at a certain pre-swelling pressure and pre-swelling temperature, and then obtaining an atractylone lipidosome mixed suspension by forcible dispersion and precipitation. The preparation process of the lipidosome is completed in the chemically inert CO2 medium; toxic organic solvents are not used, and the envelop rate of the lipidosome is improved, thereby effectively avoiding the agglomeration phenomenon caused by colliding among lipidosome particles, and ensuring the stability of the atractylone lipidosome in the preparation process.

The externally applied liquid asiaticoside preparation has effective component comprising asiaticoside 0.1-30.0 wt% and medicinal solvent 70.0-99.9 wt%. Its preparation process includes dissolving asiaticoside in the medicinal solvent, filtering, filling, sterilizing and packing. The present invention expands the clinical application of asiaticoside, and the abacterial preparation has high medicine concentration, high medicinal effect, no wound infection, and other advantages.

The invention discloses a visual laser therapeutic apparatus with dot matrixes. The visual laser therapeutic apparatus comprises a positioning insertion tube, a beam combination mirror assembly, a camera, a laser scanning assembly and a control system. The positioning insertion tube is a hollow tube and is used for positioning lesion positions and defining laser paths, and openings are formed in two ends of the hollow tube; the beam combination mirror assembly is a hollow tube, openings are formed in the hollow tube, a side opening is formed in a side surface of the beam combination mirror assembly, and one end of the beam combination mirror assembly is connected with an end of the positioning insertion tube; the camera is connected with the beam combination mirror assembly by the side opening, so that images of the lesion positions can be formed; the laser scanning assembly is connected with the other end of the beam combination mirror assembly, so that laser beams for scanning the lesion positions can be generated according to the formed images of the lesion positions; the control system is connected with the laser scanning assembly and the camera. The visual laser therapeutic apparatus with the dot matrixes has the advantages that the visual laser therapeutic apparatus is simple in operation, the cervical lesion positions can be automatically scanned by the controlled laser beams according to the preset paths and can be quickly burned through and removed, the operation time is short, the work intensity can be greatly relieved for doctors, the therapeutic efficiency can be improved, and the therapeutic success rate can be increased.

The invention provides an application of a dihydromyricetin composition in preparation of medicines for inhibiting adriamycin cardiotoxicity. The composition is composed of dihydromyricetin and adriamycin; as shown by in vivo and in vitro experimental studies, the dihydromyricetin can inhibit cell apoptosis activated by the adriamycin and dependent to mitochondrial membrane potential so as to reduce lethality caused by adriamycin cardiotoxicity, and the composition provided by the invention has excellent protection effect on cardiotoxicity induced by adriamycin. The composition provided by the invention can be used for preventing and alleviating the cardiotoxicity educed by adriamycin and has clinical practicability.

The invention relates to a method for producing total flavonoids of chrysanthemum. The method comprises the following steps of: extracting crude extracts from the chrysanthemum, and purifying the crude extracts to obtain the total flavonoids of the chrysanthemum. The method is characterized in that: the macroporous resin which is AB-8 type macroporous resin is used for purification. The content of the total flavonoids of the chrysanthemum, prepared by the method, is over 50 percent, nearly reaches 70 percent; the total flavonoids are high in purity and yield; moreover, the method is environmentally-friendly and applicable to industrial mass production.

The invention discloses a group of DNA methylation molecular markers for lung cancer and application of the DNA methylation molecular markers in preparation of a kit for early diagnosis of lung cancer. The marker is obtained through methylation of 20 gene sequences of CDO1, SOX17, TCF21, TRIM58, ITGA9, CYYR1, CLEC14A, SLIT2, ZNF677, IRX2, ACVRL1, OSR1, ADCY8, GALNT13, HSPB6, IRX1, ITGA5, PCDH17, TBX5 and TTEX1D1. Eight of the gene sequences are methylated fingerprint genes newly found in lung cancer, and the methylated fingerprint genes comprise ADCY8, GALNT13, HSPB6, IRX1, ITGA5, PCDH17, TBX5 and TTEX1D1. On the basis of the markers, a mathematical model for lung cancer diagnosis is constructed; and the model is high in sensitivity and good in specificity, the AUC can reach 0.998, and the diagnosis effect is good. The invention also discloses a method for detecting the DNA methylation marker. The DNA methylation molecular marker disclosed by the invention has good diagnostic index characteristics, can be effectively used for lung cancer diagnosis, and has relatively high clinical use and popularization values.

The invention relates to a T cell serum-free cryopreservation solution and a using method thereof. The cryopreservation solution comprises a basic culture medium, a cryopreservation protective agent and adding components which are ethanolamine, insulin, transferrin, human serum albumin, vitamin C and a cell membrane stabilizer. The cryopreservation solution disclosed by the invention has no serum,no human source and no animal source components, and is clear in chemical composition and low in DMSO content, the defect of high DMSO content in the prior art is overcome, the toxicity risk to cellsis avoided, meanwhile, possible clinical application of the cryopreservation solution is not affected, the cryopreservation solution has excellent cryopreservation performance on T cells, the resuscitation survival rate of the T cells is 90% or above after cryopreservation of the T cells, subsequent activation and amplification are not affected, and the T cell serum-free cryopreservation solutionhas high clinical application and scientific research value.

In order to improve the efficiency of gene introduction in CAR therapy employing a transposon technique, provided is a method for preparing genetically-modified T cells which express a chimeric antigen receptor, comprising: (1) a step for preparing non-proliferative cells obtained by stimulating a group of cells including T cells using an anti-CD3 antibody and an anti-CD28 antibody, and thereafter, subjecting the cells to a treatment for causing the cells to lose their proliferation capability; (2) a step for obtaining genetically-modified T cells into which a target antigen-specific chimericantigen receptor gene has been introduced using a transposon technique; (3) mixing the non-proliferative cells prepared at step (1) with the genetically-modified T cells obtained at step (2), and co-culturing the mixed cells while stimulating the mixed cells using the anti-CD3 antibody and the anti-CD28 antibody; and (4) a step for collecting the cultured cells. Also, provided is a method for preparing genetically-modified T cells which express a chimeric antigen receptor, comprising: (i) a step for preparing non-proliferative cells holding a viral peptide antigen, which cells are obtained bystimulating a group of cells including T cells using an anti-CD3 antibody and an anti-CD28 antibody, and thereafter, subjecting the cells to culturing in the presence of the viral peptide antigen anda treatment for causing the cells to lose their proliferation capability; (ii) a step for obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene hasbeen introduced using a transposon technique; (iii) mixing the non-proliferative cells prepared at step (i) with the genetically-modified T cells obtained at step (ii), and co-culturing the mixed cells; and (iv) a step for collecting the cultured cells.

The invention discloses a dihydromyricetin complex with synergistically enhanced pharmacodynamic effects. The dihydromyricetin complex comprises dihydromyricetin as a main drug and is characterized inthat the dihydromyricetin complex comprises rebaudioside A as a drug adjuvant, a mass ratio of the dihydromyricetin main drug to the rebaudioside A drug adjuvant is 1: 15 to 1: 30, and the rebaudioside A (with a CAS register number of 58543-16-1, a molecular formula C44H70O23 and molecular weight of 967.03) has purity of greater than or equal to 98%. In the aqueous solution, the rebaudioside A spontaneously forms micelles to solubilize dihydromyricetin, the solubility of dihydromyricetin is 16.57 mg/ml, the micelle has small particle sizes, a distribution range is uniform, the drug stabilityis good, the dihydromyricetin absorption after oral administration is observably improved, the oral bioavailability is improved, the rebaudioside A has activity to resist diabetes and diminish inflammation and the dihydromyricetin complex has good synergistic pharmacological activity. A preparation method of the dihydromyricetin complex has simple processes, is suitable for large-scale industrialproduction and has good economical efficiency.

The invention discloses a novel molecular marker and application thereof in preparing a kit for diagnosis and prognosis of head and neck cancer. RNA (Ribonucleic Acid) sequences of the novel molecularmarker are shown as SEQ ID NO:1 to SEQ ID NO:48. A mathematical model for diagnosing the head and neck cancer is constructed by taking the marker disclosed by the invention as a basis, and has the advantages of high sensitivity, good specificity and good diagnosis effect; AUC can be as high as 0.981; besides, 48 tRF fragments can be used as molecular markers for typing the head and neck cancer and predicting life expectancy of patients; head and neck cancer tumor samples are clustered into four subtypes according to tRFs expression in test data; the analysis of a survival curve shows that thelife expectancies of the subtypes have significant difference. The novel tRF molecular marker disclosed by the invention has good characteristics of diagnostic indicators and higher clinical use andpopularization value, and can be effectively used for diagnosis, typing and prognosis of the head and neck cancer.

The invention discloses application of a novel molecular marker to the preparation of a kit for diagnosis and prognosis of renal clear cell carcinoma. The RNA sequence of the novel molecular marker isshown in SEQ ID NO: 1 to SEQ ID NO: 57. A mathematical model for diagnosis of renal clear cell carcinoma is constructed by taking the marker as a base; the model is high in sensitivity and good in specificity, AUC can be as high as 0.997, and the diagnosis effect is good. In addition, 57 tRF fragments can serve molecular markers for classifying renal clear cell carcinoma and predicating the survival periods of patients; in test data, a renal clear cell carcinoma tumor sample is clustered into 3 subtypes according to rRFs expression, and survivorship curve analysis shows that the survival periods of the subtypes have obvious difference. The novel tRF molecular marker has excellent diagnosis index characteristic, can be effectively applied to the diagnosis, classification and prognosis of renal clear cell carcinoma, and has high clinical application and promotion values.

The present invention relates to medicinal intermediate containing higher fatty alcohol and its preparation process. The medicinal intermediate is inclusion compound containing octacosyl alcohol in 0.65-50 wt% and cyclodextrin or cyclodextrin derivative. It is prepared through a grinding process, an ultrasonic process or a saturated water solution process. The higher fatty alcohol including compound has obviously raised dissolution of octacosyl alcohol in leaching medium and thus high bioavailability. It may be further prepared into tablet, suspension or other solid or liquid preparation forms for clinical application of octacosyl alcohol.